Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay

Journal of Clinical Microbiology

Volumn 42, Issue 9, 2004, Pages 4169-4174

  Mo, Hongmei ^a   Lu, Liangjun ^a   Pithawalla, Ron ^a   Kempf, Dale J ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; LUCIFERASE; RITONAVIR; VIRUS RNA;

ARTICLE; ASSAY; CONTROLLED STUDY; GENE EXPRESSION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; HIV; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION, MISSENSE; RECOMBINANT PROTEINS; TRANSFECTION; VARIATION (GENETICS); VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 4644247968     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.9.4169-4174.2004     Document Type: Article

References (36)

1. Bi, X., H. Gatanaga, S. Ida, K. Tsuchiya, S. Matsuoka-Aizawa, S. Kimura, and S. Oka. 2003. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J. Acquir. Immune Defic. Syndr. 34:1-6.
2. Call, S. A., M. S. Saag, A. O. Westfall, J. L. Raper, S. V. Pham, J. M. Tolson, N. S. Hellmann, G. A. Cloud, and V. A. Johnson. 2001. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J. Infect. Dis. 183:401-408.
3. Cohen, C. J., S. Hunt, M. Sension, C. Farthing, M. Conant, S. Jacobson, J. Nadler, W. Verbiest, K. Hertogs, M. Ames, A. R. Rinehart, and N. M. Graham. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579-588.
4. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors, J. Virol, 71:1089-1096.
5. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
6. Frost, S. D., M. Nijhuis, R. Schuurman, C. A. Boucher, and A. J. Brown. 2000. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J. Virol. 74:6262-6268.
7. Goldblum, A. 1990. Modulation of the affinity of aspartic proteases by the mutated residues in active site models. FEBS Lett. 261:241-244.
8. Gonzales, M. J., E. Delwart, S. Y. Rhee, R. Tsui, A. R. Zolopa, J. Taylor, and R. W. Shafer. 2003. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J. Infect. Dis. 188:397-405.
9. Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vezinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
10. Hanna, G. J., and R. T. D'Aquila. 2001. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 32:774-782.
11. Harrigan, P. R., K. Hertogs, W. Verbiest, R. Pauwels, B. Larder, S. Kemp, S. Bloor, B. Yip, R. Hogg, C. Alexander, and J. S. Montaner. 1999. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 13:1863-1871.
12. Haubrich, R., and L. Demeter. 2001. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S51-S59.
13. He, J., and N. R. Landau. 1995. Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J. Virol. 69:4587-4592.
14. Hertogs, K., M. P. de Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peelers, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
15. Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:6810-6818.
16. Iga, M., Z. Matsuda, A. Okayama, W. Sugiura, S. Hashida, K. Morishita, Y. Nagai, and H. Tsubouchi. 2002. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J. Virol. Methods 106:25-37.
17. Izopet, J., C. Souyris, A. Hance, K. Sandres-Saune, M. Alvarez, C. Pasquier, F. Clavel, J. Fuel, and P. Massip. 2002. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J. Infect. Dis. 185:1506-1510.
18. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RN-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
19. Jardine, D. K., D. P. Tyssen, and C. J. Birch. 2000. Effect of protease inhibitors on HIV-1 maturation and infectivity. Antiviral Res. 45:59-68.
20. Maguire, M. F., R. Guinea, P. Griffin, S. Macmanus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. Porter, T. Wrin, N. Parkin, M. Tisdale, E. Furfine, C. Petropoulos, B. W. Snowden, and J. P. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76: 7398-7406.
21. Mammano. F., V. Trouplin, V. Zennou, and F. Clavel. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531.
22. Menzo, S., A. Monachetti, C. Balotta, S. Corvasce, S. Rusconi, S. Paolucci, F. Baldanti, P. Bagnarelli, and M. Clementi. 2003. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 17:663-671.
23. Nijhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
24. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
25. Piketty, C., E. Race, P. Castiel, L. Belec, G. Peytavin, A. Si-Mohamed, G. Gonzalez-Canali, L. Weiss, F. Clavel, and M. D. Kazatchkine. 1999. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 13:F71-F77.
26. Potash, M. J., and D. J. Volsky. 1998. Viral interference in HIV-1 infected cells. Rev. Med. Virol. 8:203-211.
27. Prado, J. G., T. Wrin, J. Beauchaine, L. Ruiz, C. J. Petropoulos, S. D. Frost, B. Clotet, R. T. D'Aquila, and J. Martinez-Picado. 2002. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16:1009-1017.
28. Rayner, M. M., B. Cordova, and D. A. Jackson. 1997. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections. Virology 236:85-94.
29. Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15:247-277.
30. Taddeo, B., M. Federico, F. Titti, G. B. Rossi, and P. Verani. 1993. Homologous superinfection of both producer and nonproducer HIV-infected cells is blocked at a late retrotranscription step. Virology 194:441-452.
31. Tessmer, U., and H. G. Krausslich. 1998. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J. Virol. 72:3459-3463.
32. Todd, M. J., I. Luque, A. Velazquez-Campoy, and E. Freire. 2000. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 39:11876-11883.
33. Vasudevachari, M. B., Y. M. Zhang. H. Imamichi, T. Imamichi, J. Falloon, and N. P. Salzman. 1996. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob. Agents Chemother. 40:2535-2541.
34. Wilson, J. W. 2003. Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS (Reading) 13:25-30, 35-38.
35. Xie, D., S. Gulnik, E. Gustchina, B. Yu, W. Shao, W. Qoronfleh. A. Nathan, and J. W. Erickson. 1999. Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8:1702-1707.
36. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Monloya, P. Hsu, D. Katzenstein, T. C. Merigan. and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.